CLSA analyst Jeffrey Chan upgrades New Oriental Education (NYSE:EDU) from Outperform to Buy.
Vaxcyte Exercises Option And Enters Into Manufacturing Rights Agreement With Sutro Biopharma To Obtain Control Over Manufacturing And Development Of Cell-Free Extract For Its Vaccine Candidates
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company's Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement
